Schering Corporation

Elizabeth B Smith

Michael J Ryan

Jason Arnold Lotvin

Suke Wang

George H Miller

Maureen Laverty

Frederick James Monsma, Jr

Eric L Gustafson

Karen J Shaw

Xiaoxin Yang

Hanan K Munayyer

The invention relates to the use of the interaction between the GPR78 polypeptide or the GPR26 polypeptide and their identified ligands and antagonists as the basis for screening methods for the identification of agents that modulate the activity of these receptors, and for diagnostic and therapeutic purposes. The agents identified by the screening methods of the invention have use in the treatment of GPR78- and/or GPR26-mediated disorders, including, but not limited to, neurological disorders (such as anxiety disorders), metabolic disorders, cardiovascular disorders, hormone-related disorders, vascular disorders and hyperproliferative disorders (such as cancer).

Modulators of the orphan G protein-coupled receptors GPR78 and GPR26

7-Chloro-8-methoxytetracycline isolated from antibiotic ES-119 and antibiotic Tet. 7 which are produced by fermentation of mutants of Actinomadura brunnea, namely Actinomadura brunnea var. antibiotica, ATCC 53108 and Actinomadura brunnea var antibiotica ATCC 53180 and its use as an antibiotic against gram-positive and gram-negative organisms are disclosed.

Actinomadura brunnea var. antibiotica strains

Methods of constructing and using gene expression systems to indicate the pertubation of fungal cell envelopes are provided. The recombinant genes produce indicator cleavage enzymes such as .beta.-galactosidase when galactose is able to enter the cell, despite the presence of glucose, through discontinuous cell envelopes. The indicator cleavage enzymes such as .beta.-galactosidase cleaves a colorimetric indicator placed in the media to produce an easily detected measurement of altered cell envelope permeability.

Colorimetric assay for detecting fungal cell envelope perturbations

Growing community of inventors

Plainsboro, NJ, United States of America

Elizabeth B Smith